Tazemetostat(TAZVERIK) is a targeted drug used to treat epithelioid sarcoma and follicular lymphoma. It blocks the growth and spread of lesion cells by inhibiting EZH2 methyltransferase. Tazemetostat showed good efficacy in clinical trials, significantly prolonging the patient's survival.

Tazemetostat(TAZVERIK) showed good efficacy and extended the patient's survival

Tazemetostat is an EZH2 methyltransferase inhibitor, mainly used to treat metastatic or locally advanced epithelioid sarcoma that cannot be completely resected, as well as recurrent or refractory follicular lymphoma. It significantly prolongs the patient's survival by inhibiting the activity of EZH2 and blocking the growth and spread of lesion cells.

The mechanism of action of Tazemetostat

Tazemetostat blocks the epigenetic regulation of lesion cells by inhibiting the activity of EZH2 methyltransferase, thereby inhibiting the growth and spread of lesions. This mechanism of action makes it show significant efficacy in the treatment of epithelioid sarcoma and follicular lymphoma.

Tazemetostat's indications

Tazemetostat is suitable for non-completely resectable metastatic or locally advanced epithelioid sarcoma in children and adults aged 16 years and older. It is also suitable for patients with recurrent or refractory follicular lymphoma, especially those with EZH2 mutations.

Tazemetostat has significant efficacy, but patients need to pay attention to its storage method when using it. Let’s learn about Tazemetostat’s storage method together below.

How to store Tazemetostat？

The storage of tazestal requires special attention to temperature, humidity and light conditions. Patients should follow the following suggestions when storing to avoid the influence of moisture, light or temperature changes in the drug.

Temperature control

Tazemetostat should be stored at room temperature below 30°C to avoid exposure of the drug to extremely high or low temperature environments. Freezing may cause changes in the structure and efficacy of the drug, affecting its therapeutic effect.

Moisture-proof and moisture-proof

Tazemetostat should be stored in a dry and well-ventilated place to prevent the drug from getting damp. Changes in humidity may have a negative impact on the stability of Tazemetostat. Try to avoid switching in humid and dry environments during storage.

Special attention is required for storage of Tazemetostat. We will introduce Tazemetostat's missed service measures.

Tazemetostat's missed measures

The recommended dose of Tazemetostat is 800 mg twice a day, oral administration may be accompanied by oral administration without food. If the patient misses one dose or vomits after taking it, the following recommendations should be taken.

Missed service handling

If the patient misses a dose of Tazemetostat and is more than 6 hours away from the next dose, the dose should be skipped and the next dose should be taken at the regular time of the next day. Do not replenish missed doses to avoid overdose.

Treatment after vomiting

If the patient vomits after taking Tazemetostat, no additional dose should be supplemented, but continue to take the next dose according to the medication plan. Vomiting may lead to incomplete absorption of the drug, but re-administering doses may increase the risk of adverse reactions.

Tazemetostat is a prescription drug. Patients should strictly follow the doctor's instructions when using it, conduct regular reviews to prevent possible serious adverse reactions.